Experimental Respiratory Infection with Type 4 Adenovirus Vaccine in Volunteers: Clinical and Immunological Responses
| Autor: | Thomas J. Smith, Edward L. Buescher, William A. Altemeier, J. M. McCown, Franklin H. Top |
|---|---|
| Rok vydání: | 1970 |
| Předmět: |
Male
Adenoviridae Infections Prevalence Capsules Nose Biology Antibodies Virus Adenoviridae Placebos Blood serum Species Specificity Neutralization Tests medicine Humans Immunology and Allergy Serotyping Respiratory Tract Infections Respiratory tract infections Vaccination Respiratory infection Viral Vaccines Virology Solutions Adenovirus vaccine Immunity Active Infectious Diseases Immunization Antibody Formation Immunology Pharynx Digestive System medicine.drug |
| Zdroj: | Journal of Infectious Diseases. 122:239-248 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1093/infdis/122.4.239 |
| Popis: | ered acceptable or optimally effective [1, 2]. A living type 4 adenovirus (AV-4) vaccine developed by Chanock et al. [3] offers promise for control of type-specific disease. This entericcoated tablet has been administered orally to approximately 350,000 recruits by several investigative groups over the past several years, and has been shown effective in preventing ARD due to AV-4 [4-6]. However, in a study in 1966 at Fort Dix, New Jersey, reduction in ARD following vaccination was followed by increased incidence of ARD due to adenovirus type 7 (AV-7). Before introduction of vaccine, this virus was responsible for insignificant amounts of ARD; following suppression of AV-4, it predominated as the cause of respiratory disease, and total rates for ARD approached those before immunization [5]. The same phenomenon has been |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|